No recent analyst price targets found for BAL.
Latest News for BAL
Agenus Announces Three-Year Survival Data from Phase 1b BOT+BAL Study in MSS Metastatic Colorectal Cancer to be Presented at ESMO GI 2026
[url="]Agenus[/url] Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that three-year survival data from the Phase 1b C-800-01 study
🧮 Earnings Move Analyzer
Insider Trading
No insider trades found for BAL.
Senate Trading
No Senate trades found for BAL.
U.S. House Trading
No House trades found for BAL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.